An observational study in to Contribute to a Better Control of COVID-19 in Children in Niger, sponsored by Centre de Recherche Médicale et Sanitaire. Completed at 1 site in Niger. Open to participants aged 0 Years to 15 Years. Per ClinicalTrials.gov, last updated 2023-06-02.
Sponsored by Centre de Recherche Médicale et Sanitaire · Observational
On January 30, 2020, the WHO declared COVID-19 a global health emergency. Children were affected with less severe forms. Niger had implemented measures in a context where children are a source of contamination. The objective was to determine the factors associated with COVID-19 in children in Niger from February to August 2020 through an analysis of the national database.
We conducted an analytical cross-sectional study including all COVID-19 suspects in the database. We used Excel and Epi Info 7.2.4. software for data extraction and analysis. Frequencies and proportions were calculated, we estimated in a logistic regression the OR of association with their 95% confidence interval, the factors associated with COVID-19 at the threshold of p\<0.05.
Results: Of 572 notified suspected COVID-19 cases in children aged 0-15 years, 11.36% were positive. The median age of infected children was 10 years [IQR: 5- 13 years]. The sex ratio of males to females was 2.1. Children aged 11-15 years were 49.2%, 61.5% resided in Niamey, 4.6% had comorbidities. The notion of travel was 12.3% and 40% had a notion of contact, 24.4% had a fever, 23.2% had a cough, 18% were hospitalized and the case fatality was 1.5%. In etiological analysis, the factors associated with COVID-19 were sex ORa= 0.51 [0.28-0.93] p=0.028, the presence of symptoms ORa= 2.29 [1.23-4.25] p=0.008 and the notion of contact ORa= 0.32 [0.13-0.77] p=0.011.
exposed children were sensitive to COVID-19, all age groups were affected with a male predominance. We recommend barrier measures adapted to young people, early detection and management of infected children.
7,990 studies on the registry are indexed under COVID-19; 466 are open to participants now.
This study's enrollment of 572 is above the median of 268 across 3,208 observational studies indexed under COVID-19.
Browse COVID-19 studies →This is the only study on the registry with Centre de Recherche Médicale et Sanitaire as lead sponsor.
Counted across the registry records on this site, refreshed daily.
This was an analytical cross-sectional study with retrospective collection of epidemiological surveillance data on COVID-19 in Niger. The study period spanned six (6) months from February 25 to August 28, 2020. Children aged 0-15 years suspected of having COVID-19 whose data were in the DSRE database were included. We used the data extraction form that served as a secondary database containing only our variables of interest.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
analytical cross-sectional study with retrospective collection of epidemiological surveillance data on COVID-19 in Niger.
data base analysis
The first step concerned the descriptive part where the frequencies, proportions, means and extreme values of the variables were calculated. Some of these variables were presented in the form of tables and graphs.
Time frame: May 2021
Plan to share: No — What is IPD ?
No publications or documents are linked to this record.
Ran from Feb 2020 to primary completion in Aug 2020, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.